MoonLake Announces Week 52 Results of Sonelokimab from its Phase 3 VELA Program in Hidradenitis Suppurativa and Confirms Investor Day on June 22, 2026

Impact · against what's priced in

MoonLake (MLTX) demonstrates best-in-class potential with Week 52 data showing superior efficacy over a competing IL-17-A & F inhibitor and strong results in adolescents. The data reinforces the drug's commercial profile through durable responses and high patient retention, serving as a significant positive catalyst for valuation.

MLTX+0.80

No priced-in read yet